Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers

Journal of Clinical Pharmacology

Volumn 38, Issue 11, 1998, Pages 1063-1071

  Strenkoski Nix, Laura C ^a,b   Forrest, Alan ^a   Schentag, Jerome J ^a   Nix, David E ^a,c  

^a Millard Fillmore Gates Circle Hospital   (United States)

^b Pharmaceutical Consulting   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG METABOLISM; ENTEROBACTER CLOACAE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE; MALE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PSEUDOMONAS AERUGINOSA; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STAPHYLOCOCCUS AUREUS;

EID: 0031786049     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009803801112     Document Type: Article

References (30)

1. Sande MA: Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med 1980;92:290-295.
2. Young LS: Combination or single drug therapy for gram-negative sepsis. In, Remington JS, Swartz MV (eds.): Current Clinical Topics in Infectious Diseases. New York: McGraw-Hill, 1982;177-205.
3. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR: Antibiotic Therapy of Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-546.
4. Hopefl AW: Overview of synergy with reference to double beta-lactam combinations. Drug Intell Clin Pharm 1991;25:972-977.
5. Flaherty JP, Waitley D, Edlin B, George D, Arnow P, O'Keefe P, Weinstein RA: Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med 1989;87(suppl 5A): 278S-282S.
6. Philpott-Howard JN, Barker KF, Wade JJ, Kaczmarski RS, Smedley JC, Mufti GJ: Randomized multicentre study of ciprofloxacin and azlocillin versus gentamicin and azlocillin in the treatment of febrile neutropenic patients. J Antimicrob Chemother 1990;26(Suppl F):89-99.
7. Hyatt DS, Rogers TRF, McCarthy DM, Samson DS: A randomized trial of ciprofloxacin plus azlocillin versus netilmicin plus azlocillin for the empirical treatment of fever in neutropenic patients. J Antimicrob Chemother 1991;28:324-326.
8. Samuelsson J, Nilsson P, Wahlin A, Lerner R, Winqvist I, Palmblad J: A pilot study of piperacillin and ciprofloxacin as initial therapy for fever in severely neutropenic leukemia patients. Scand J Infect Dis 1992;24:467-475.
9. Nix DE, Ballow CH, Forrest A, Paladino JA, Birmingham MC, Gumbo TJ, Schentag JJ: Dosing considerations with intravenous ciprofloxacin in critical care patients. In, Gemmell CG (ed.): Ciprofloxacin in Hematology and Oncology. New York: Raven Press, 1993;45-55.
10. Gerber AU, Brugger HP, Feller C, Stritzko T, Stalder B: Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice:comparison of murine and human pharmacokinetics. J Infect Dis 1986;153:90-97.
11. Eliopoulos GM, Moellering RC: Antimicrobial combinations. In, Lorian V (ed.): Antibiotics in Laboratory Medicine. Third edition. Baltimore: Williams and Wilkins, 1991;432-492.
12. Drake TA, Hackbarth CJ, Sande MA: Value of serum tests in combined drug therapy of endocarditis. Antimicrob Agents Chemother 1983;24:653-657.
13. Coppens L, Hansen B, Klastersky J: Therapy of staphylococcal infections with cefamandole alone or vancomycin alone or with a combination of cefamandole and tobramycin. Antimicrob Agents Chemother 1983;23:36-41.
14. Barriere SL, Ely E, Kapusnik JE, Gambertoglio JG: Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother 1985;16:49-59.
15. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37: 1073-1081.
16. Schentag JJ, Nix DE, Adelman MH: Mathematical examination of dual individualization principles. I. Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Drug Intell Clin Pharm 1991;25:1050-1057.
17. Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ: Mathematical examination of dual individualization principles. II. The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994;28:863-868.
18. Leggett JE, Wolz SA, Craig WA: Use of serum ultrafiltrate in the serum dilution test. J Infect Dis 1989;160:616-623.
19. Colaizzi PA, Polk RE, Poynor WJ, Raffalovich AC, Cefali EA, Beightol LA: Comparative pharmacokinetics of azlocillin and piperacillin in normal adults. Antimicrob Agents Chemother 1986; 29:938-940.
20. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
21. King TC, Schlessinger D, Krogstad DJ: The assessment of drug combinations. Rev Infect Dis 1981;3:627-633.
22. Sörgel F, Kinzig M: Pharmacokinetic characteristics of piperacillin/tazohactam. Intensive Care Med 1994;20:S14-S20.
23. Karabalut N, Drusano GL: Pharmacokinetics of the quinolone antimicrobial agents. In, Hooper DC, Wolfson JS (eds.): Quinolone Antimicrobial Agents. Second edition. Washington, DC: American Society for Microbiology, 1993;195-223.
24. Barriere SL, Catlin DH, Orlando PL, Noe A, Frost RW: Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrob Agents Chemother 1990;34:823-826.
25. Leggett JE, Craig WA: Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram negative bacilli. Antimicrob Agents Chemother 1989;33:35-40.
26. Haller I: Comprehensive evaluation of ciprofloxacin in combination with β-lactam antibiotics against Enterobacteriaceae and Pseudomonas aeruginosa. Arzneimittelforschung 1986;36:226-229.
27. Bustamante CI, Wharton RC, Wade JC: In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:1814-1815.
28. Chow AW, Wong J, Bartlett KH, Shafran SD, Stiver HG: Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum β-lactams, and aminoglycosides and susceptibility to antibiotic combinations. Antimicrob Agents Chemother 1989;33: 1368-1372.
29. Meyer RD, Liu S: In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1988;11:151-157.
30. Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli, C, Klatersky J, Glauser M: Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob Agents Chemother 1991;35: 873-878.